收稿日期: 2020-07-17
网络出版日期: 2021-04-06
基金资助
国家自然科学基金(81671481)
Research progress of hydroxychloroquine in reproductive immunology
Received date: 2020-07-17
Online published: 2021-04-06
Supported by
National Natural Science Foundation of China(81671481)
寇禧 , 赵爱民 . 羟氯喹应用于生殖免疫领域的研究进展[J]. 上海交通大学学报（医学版）, 2021 , 41(3) : 380 -385 . DOI: 10.3969/j.issn.1674-8115.2021.03.017
Hydroxychloroquine (HCQ) is a kind of synthetic 4-aminoquinoline antimalarial drugs. In recent years, other pharmacological effects of HCQ, such as immunomodulatory, immunosuppression, anti-inflammation, vascular endothelium protection, anti-thrombus, improving metabolic syndrome, and anti-infection, have been gradually known. At present, HCQ is a first-line drug for systemic lupus erythematosus. And in many guidelines for the treatment of autoimmune diseases, HCQ is recommended during whole pregnancy and lactation. This review mainly expounds the mechanism and research progress of HCQ in reproductive immunology, including pregnancy complicated with autoimmune diseases, such as systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome, as well as unexplained recurrent spontaneous abortion and recurrent implantation failure, and explores the safety and application prospect of HCQ in reproductive immunology.
Key words： hydroxychloroquine (HCQ); reproductive immunology; pregnancy; drug mechanism; safety
| 1 | 余春晓, 李杏, 孙尔维. 羟氯喹抗风湿病的辛路历程[J]. 中华风湿病学杂志, 2018, 22(1): 35-37. |
| 2 | Hu C, Lu L, Wan JP, et al. The pharmacological mechanisms and therapeutic activities of hydroxychloroquine in rheumatic and related diseases[J]. Curr Med Chem, 2017, 24(20): 2241-2249. |
| 3 | Balevic SJ, Cohen-Wolkowiez M, Eudy AM, et al. Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes[J]. J Rheumatol, 2019, 46(1): 57-63. |
| 4 | Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study[J]. Lupus, 2001, 10(6): 401-404. |
| 5 | Eudy AM, Siega-Riz AM, Engel SM, et al. Effect of pregnancy on disease flares in patients with systemic lupus erythematosus[J]. Ann Rheum Dis, 2018, 77(6): 855-860. |
| 6 | Koh JH, Ko HS, Kwok SK, et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus[J]. Lupus, 2015, 24(2): 210-217. |
| 7 | Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy[J]. Arthritis Rheum, 2006, 54(11): 3640-3647. |
| 8 | Zhan Z, Yang Y, Zhan Y, et al. Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus[J]. PLoS One, 2017, 12(4): e0176457. |
| 9 | Seo MR, Chae J, Kim YM, et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia[J]. Lupus, 2019, 28(6): 722-730. |
| 10 | de Moreuil C, Alavi Z, Pasquier E. Hydroxychloroquine may be beneficial in preeclampsia and recurrent miscarriage[J]. Br J Clin Pharmacol, 2020, 86(1): 39-49. |
| 11 | Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE)[J]. Expert Opin Drug Saf, 2017, 16(3): 411-419. |
| 12 | 赵小娟, 汪国生. 抗疟药在系统性红斑狼疮中的作用进展[J]. 中华临床医师杂志(电子版), 2012, 6(7): 1799-1801. |
| 13 | Ben-Zvi I, Kivity S, Langevitz P, et al. Hydroxychloroquine: from malaria to autoimmunity[J]. Clin Rev Allergy Immunol, 2012, 42(2): 145-153. |
| 14 | Schroeder ME, Russo S, Costa C, et al. Pro-inflammatory Ca2+-activated K+ channels are inhibited by hydroxychloroquine[J]. Sci Rep, 7(1): 1-7. |
| 15 | Nuri E, Taraborelli M, Andreoli L, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome[J]. Immunol Res, 2017, 65(1): 17-24. |
| 16 | Be?arevi? M. Detrimental roles of TNF-α in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-α[J]. J Thromb Thrombolysis, 2017, 44(4): 565-570. |
| 17 | Johnson R, Charnley J. Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty[J]. Clin Orthop Relat Res, 1979(144): 174-177. |
| 18 | Le NT, Takei Y, Izawa-Ishizawa Y, et al. Identification of activators of ERK5 transcriptional activity by high-throughput screening and the role of endothelial ERK5 in vasoprotective effects induced by statins and antimalarial agents[J]. J Immunol, 2014, 193(7): 3803-3815. |
| 19 | Godo S, Shimokawa H. Endothelial functions[J]. Arterioscler Thromb Vasc Biol, 2017, 37(9): e108-e114. |
| 20 | Virdis A, Tani C, Duranti E, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus[J]. Arthritis Res Ther, 2015, 17: 277. |
| 21 | Li HZ, Xu XH, Lin N, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis, 2019, 78(3): e21. |
| 22 | 王茂竹, 李法琦. 羟氯喹预防类风湿关节炎患者动脉粥样硬化的机制研究[J]. 重庆医学, 2016, 45(14): 1995-1997. |
| 23 | Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century[J]. Int J Antimicrob Agents, 2007, 30(4): 297-308. |
| 24 | 中国系统性红斑狼疮研究协作组专家组, 国家风湿病数据中心. 中国系统性红斑狼疮患者围产期管理建议[J]. 中华医学杂志, 2015, 95(14): 1056-1060. |
| 25 | Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(6): 736-745. |
| 26 | 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185. |
| 27 | Albert CR, Schlesinger WJ, Viall CA, et al. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function[J]. Am J Reproductive Immunol, 2014, 71(2): 154-164. |
| 28 | Meroni PL. Prevention & treatment of obstetrical complications in APS: is hydroxychloroquine the Holy Grail we are looking for?[J]. J Autoimmun, 2016, 75: 1-5. |
| 29 | Abrahams VM, Chamley LW, Salmon JE. Emerging treatment models in rheumatology: antiphospholipid syndrome and pregnancy: pathogenesis to translation[J]. Arthritis Rheumatol, 2017, 69(9): 1710-1721. |
| 30 | Mekinian A, Lazzaroni MG, Kuzenko A, et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study[J]. Autoimmun Rev, 2015, 14(6): 498-502. |
| 31 | Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies[J]. Am J Obstet Gynecol, 2016, 214(2): 273.e1-273.e8. |
| 32 | Belizna C, Pregnolato F, Abad S, et al. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome[J]. Autoimmun Rev, 2018, 17(12): 1153-1168. |
| 33 | Schreiber K, Breen K, Cohen H, et al. HYdroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies (HYPATIA) protocol: a multinational randomized controlled trial of hydroxychloroquine versus placebo in addition to standard treatment in pregnant women with antiphospholipid syndrome or antibodies[J]. Semin Thromb Hemost, 2017, 43(6): 562-571. |
| 34 | Mekinian A, Vicaut E, Cohen J, et al. Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase Ⅱ multicenter randomized trial, HYDROSAPL[J]. Gynecol Obstet Fertil Senol, 2018, 46(7/8): 598-604. |
| 35 | Limper M, de Leeuw K, Lely AT, et al. Diagnosing and treating antiphospholipid syndrome: a consensus paper[J]. Neth J Med, 2019, 77(3): 98-108. |
| 36 | Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019, 78(10): 1296-1304. |
| 37 | Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sj?gren's syndrome with topical and systemic therapies[J]. Ann Rheum Dis, 2020, 79(1): 3-18. |
| 38 | Rainsford KD, Parke AL, Clifford-Rashotte M, et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases[J]. Inflammopharmacology, 2015, 23(5): 231-269. |
| 39 | Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus[J]. Circulation, 2012, 126(1): 76-82. |
| 40 | Morel N, Georgin-Lavialle S, Levesque K, et al. ? Lupus néonatal ?: revue de la littérature[J]. La Revue De Médecine Interne, 2015, 36(3): 159-166. |
| 41 | Lu LJ. Immunosuppressant Regimens for Living Fetuses Study[DB/OL]. (2019-08-12)[2020-03-15]. . |
| 42 | 韦相才, 朱伟杰, 钟兴明. 生殖免疫学理论与临床新进展[M]. 北京: 科学出版社, 2015. |
| 43 | Kang XM, Zhang XX, Liu ZL, et al. Excessive TLR9 signaling contributes to the pathogenesis of spontaneous abortion through impairment of Treg cell survival by activation of Caspase 8/3[J]. Int Immunopharmacol, 2015, 29(2): 285-292. |
| 44 | Pasquier E, de Saint-Martin L, Marhic G, et al. Hydroxychloroquine for prevention of recurrent miscarriage: study protocol for a multicentre randomised placebo-controlled trial BBQ study[J]. BMJ Open, 2019, 9(3): e025649. |
| 45 | Nielsen HS. Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss[DB/OL]. (2020-03-12)[2020-03-15]. . |
| 46 | Mekinian A, Cohen J, Alijotas-Reig J, et al. Unexplained recurrent miscarriage and recurrent implantation failure: is there a place for immunomodulation?[J]. Am J Reprod Immunol, 2016, 76(1): 8-28. |
| 47 | 赵义, 李小霞. 用辩证的眼光看待羟氯喹的用药安全[J]. 药物不良反应杂志, 2015, 17(3): 164-166. |
| 48 | Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1, 207 patients in a large multicenter outpatient practice[J]. Arthritis Rheum, 1997, 40(8): 1482-1486. |
| 49 | Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update[J]. Curr Opin Rheumatol, 2018, 30(3): 249-255. |
| 50 | Prayuenyong P, Kasbekar AV, Baguley DM. Clinical implications of chloroquine and hydroxychloroquine ototoxicity for COVID-19 treatment: a mini-review[J]. Front Public Health, 2020, 8: 252. |
| 51 | Chatre C, Roubille F, Vernhet H, et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature[J]. Drug Saf, 2018, 41(10): 919-931. |
| 52 | Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group[J]. Arthritis Rheum, 2003, 48(11): 3207-3211. |
| 53 | Sperber K, Hom C, Chao CP, et al. Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases[J]. Pediatr Rheumatol Online J, 2009, 7: 9. |
| 54 | Osadchy A, Ratnapalan T, Koren G. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature[J]. J Rheumatol, 2011, 38(12): 2504-2508. |
| 55 | Motta M, Tincani A, Faden D, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation[J]. J Perinatol, 2005, 25(2): 86-89. |
| 56 | Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids[J]. Rheumatology (Oxford), 2016, 55(9): 1693-1697. |
| 57 | G?testam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation[J]. Ann Rheum Dis, 2016, 75(5): 795-810. |
/
| 〈 |
|
〉 |